Sven Stegemann

2.5k total citations
50 papers, 1.9k citations indexed

About

Sven Stegemann is a scholar working on Economics and Econometrics, Geriatrics and Gerontology and Pharmaceutical Science. According to data from OpenAlex, Sven Stegemann has authored 50 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 13 papers in Geriatrics and Gerontology and 12 papers in Pharmaceutical Science. Recurrent topics in Sven Stegemann's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Pharmaceutical Practices and Patient Outcomes (13 papers) and Pharmaceutical studies and practices (11 papers). Sven Stegemann is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Pharmaceutical Practices and Patient Outcomes (13 papers) and Pharmaceutical studies and practices (11 papers). Sven Stegemann collaborates with scholars based in Austria, United Kingdom and Germany. Sven Stegemann's co-authors include F. Leveiller, Hidde de Jong, Hans H. Lindén, D. Franchi, Jörg Breitkreutz, M. Gosch, Diana A. van Riet‐Nales, Amrit Paudel, Massimo Bresciani and Graziano Onder and has published in prestigious journals such as International Journal of Pharmaceutics, Drug Discovery Today and Colloids and Surfaces B Biointerfaces.

In The Last Decade

Sven Stegemann

49 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sven Stegemann Austria 19 712 304 285 212 196 50 1.9k
Matthew Roberts United Kingdom 24 830 1.2× 109 0.4× 343 1.2× 228 1.1× 114 0.6× 56 2.1k
Kamran Khan United Kingdom 19 991 1.4× 332 1.1× 285 1.0× 131 0.6× 162 0.8× 76 2.0k
Talia Flanagan United Kingdom 18 550 0.8× 197 0.6× 282 1.0× 181 0.9× 48 0.2× 42 1.1k
Loyd V Allen United States 20 704 1.0× 155 0.5× 387 1.4× 182 0.9× 94 0.5× 139 2.1k
D.M. Barends Netherlands 35 1.4k 2.0× 432 1.4× 400 1.4× 412 1.9× 158 0.8× 68 3.1k
A. Li Wan Po United Kingdom 28 497 0.7× 148 0.5× 132 0.5× 301 1.4× 94 0.5× 117 2.5k
Sandra Klein Germany 27 1.9k 2.7× 580 1.9× 589 2.1× 368 1.7× 103 0.5× 99 3.0k
James L. Ford United Kingdom 36 2.7k 3.8× 757 2.5× 593 2.1× 374 1.8× 72 0.4× 100 4.0k
Dale P. Conner United States 24 744 1.0× 235 0.8× 594 2.1× 374 1.8× 222 1.1× 56 2.7k
Hye Sun Gwak South Korea 23 343 0.5× 56 0.2× 160 0.6× 257 1.2× 173 0.9× 176 2.1k

Countries citing papers authored by Sven Stegemann

Since Specialization
Citations

This map shows the geographic impact of Sven Stegemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Stegemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Stegemann more than expected).

Fields of papers citing papers by Sven Stegemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Stegemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Stegemann. The network helps show where Sven Stegemann may publish in the future.

Co-authorship network of co-authors of Sven Stegemann

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Stegemann. A scholar is included among the top collaborators of Sven Stegemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Stegemann. Sven Stegemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stegemann, Sven, Anna Birna Almarsdóttir, & Charlotte Vermehren. (2023). Patient engagement in pharmaceutical development: Where are we? – Report from a symposium. European Journal of Pharmaceutics and Biopharmaceutics. 185. 1–4. 1 indexed citations
2.
Stegemann, Sven, et al.. (2023). Patient-centric drug product development: Acceptability across patient populations – Science and evidence. European Journal of Pharmaceutics and Biopharmaceutics. 188. 1–5. 4 indexed citations
3.
Stegemann, Sven, et al.. (2022). An evaluation of film coating materials and their predicted oro-esophageal gliding performance for solid oral dosage forms. Journal of Drug Delivery Science and Technology. 77. 103804–103804. 2 indexed citations
4.
Buttgereit, Thomas, Andriko Palmowski, Maarten Boers, et al.. (2021). Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trials. Age and Ageing. 50(6). 1988–1996. 30 indexed citations
5.
6.
7.
Stegemann, Sven, et al.. (2020). Challenges and opportunities to include patient‐centric product design in industrial medicines development to improve therapeutic goals. British Journal of Clinical Pharmacology. 86(10). 2020–2027. 18 indexed citations
8.
Stegemann, Sven, et al.. (2019). An evaluation of the gliding performance of solid oral dosage form film coatings using an artificial mucous layer. Colloids and Surfaces B Biointerfaces. 177. 235–241. 6 indexed citations
9.
Stegemann, Sven, et al.. (2018). Polymer adhesion predictions for oral dosage forms to enhance drug administration safety. Part 2: In vitro approach using mechanical force methods. Colloids and Surfaces B Biointerfaces. 166. 17–23. 12 indexed citations
10.
11.
Stegemann, Sven. (2016). Towards better understanding of patient centric drug product development in an increasingly older patient population. International Journal of Pharmaceutics. 512(2). 334–342. 15 indexed citations
12.
Stegemann, Sven. (2014). Increasing complexity of drug therapy in older adults and the importance of adherence monitoring. 1 indexed citations
13.
Stegemann, Sven, et al.. (2014). Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models. Zeitschrift für Gerontologie und Geriatrie. 47(4). 285–287. 8 indexed citations
14.
Stegemann, Sven, Paul Connolly, W. Stephen Matthews, et al.. (2014). Application of QbD Principles for the Evaluation of Empty Hard Capsules as an Input Parameter in Formulation Development and Manufacturing. AAPS PharmSciTech. 15(3). 542–549. 11 indexed citations
15.
Messina, Rossella, et al.. (2014). Results from a preliminary review of scientific evidence for appropriateness of preparations, dosage forms and other product design elements for older adult patients. International Journal of Pharmaceutics. 478(2). 822–828. 18 indexed citations
16.
Stegemann, Sven, M. Gosch, & Jörg Breitkreutz. (2012). Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. International Journal of Pharmaceutics. 430(1-2). 197–206. 166 indexed citations
17.
Stegemann, Sven, Imre Klebovich, István Antal, et al.. (2011). Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. European Journal of Pharmaceutical Sciences. 44(4). 447–454. 15 indexed citations
18.
Stegemann, Sven, et al.. (2009). Self-Emulsifying Drug Delivery Systems: Facing the bioavailability challenge in drug delivery. 71(8). 1409–1416.
19.
Stegemann, Sven. (2007). When poor solubility becomes an issue: from early stage to proof of concept. 331 indexed citations
20.
Stegemann, Sven. (2005). Colored capsules - : a contribution to drug safety. 67(9). 1088–1095. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew Roberts Breakdown of academic impact, for papers by Kamran Khan Breakdown of academic impact, for papers by Talia Flanagan Breakdown of academic impact, for papers by Loyd V Allen Breakdown of academic impact, for papers by D.M. Barends Breakdown of academic impact, for papers by A. Li Wan Po Breakdown of academic impact, for papers by Sandra Klein Breakdown of academic impact, for papers by James L. Ford Breakdown of academic impact, for papers by Dale P. Conner Breakdown of academic impact, for papers by Hye Sun Gwak
Rankless by CCL
2026